Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026)
Nuvectis Pharma (NVCT) reported Income from Continuing Operations of 7144000.0 for Q1 2026, little changed on a YoY basis from 7152017.96 in Q1 2025, and up 14.39% sequentially from 8345000.0 in Q4 2025.
Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 6 years of Income from Continuing Operations data on file, last reported at 7144000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations changed 0.11% year-over-year to 7144000.0; the trailing twelve-month figure through Mar 2026 stood at 30786000.0 (up 27.89% YoY), and the FY2025 full-year result was 27473000.0, up 28.69% from the prior year.
- Income from Continuing Operations climbed to 7144000.0 in Q1 2026, from 8345000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3930000.0 in Q1 2022 to a low of 25776000.0 in Q4 2024.
- A 5-year average of 11012941.18 and a median of 8345000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 303.28% in 2023 and surged 73.86% in 2024, its largest moves.
- Tracing NVCT's Income from Continuing Operations over 5 years: stood at 15269000.0 in 2022, then plunged by 38.27% to 21113000.0 in 2023, then retreated by 22.09% to 25776000.0 in 2024, then jumped by 67.62% to 8345000.0 in 2025, then climbed by 14.39% to 7144000.0 in 2026.
- Business Quant data shows NVCT's Income from Continuing Operations at 7144000.0 in Q1 2026, 8345000.0 in Q4 2025, and 7960000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Nuvectis Pharma | 453.54 Mn | 453.54 Mn | - | -7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | -7.96 Mn |
| Jun 30, 2025 | -7.34 Mn |
| Mar 31, 2025 | -7.14 Mn |
| Dec 31, 2024 | -25.78 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -5.03 Mn |
| Mar 31, 2024 | -13.81 Mn |
| Dec 31, 2023 | -21.11 Mn |
| Sep 30, 2023 | -18.15 Mn |
| Jun 30, 2023 | -9.70 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.27 Mn |
| Sep 30, 2022 | -8.64 Mn |
| Jun 30, 2022 | -7.28 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Sep 30, 2021 | -4.67 Mn |
| Jun 30, 2021 | -5.94 Mn |